Exhibit 4.4
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING THESE SECURITIES, AGREES FOR THE BENEFIT OF FUSION PHARMACEUTICALS INC. (THE “CORPORATION”) THAT SUCH SECURITIES MAY BE SOLD OR TRANSFERRED ONLY (A) TO THE CORPORATION, (B) IN COMPLIANCE WITH RULE 144A UNDER THE U.S. SECURITIES ACT, IF AVAILABLE, (C) IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (D) IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PURSUANT TO RULE 144 UNDER THE U.S. SECURITIES ACT, IF AVAILABLE, OR (E) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE UNITED STATES STATE SECURITIES LAWS, AND IN EACH CASE, IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS OF THE UNITED STATES, AND IN THE CASE OF (D) AND (E) ABOVE THE SELLER FURNISHES TO THE CORPORATION AND THE CORPORATION’S TRANSFER AGENT AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.
WARRANT CERTIFICATE
FUSION PHARMACEUTICALS INC.
(a corporation incorporated under theCanada Business Corporations Act
and having its principal office at 270 Longwood Rd. S., Hamilton, Ontario, Canada L8P 0A6)
CLASS B PREFERRED SHARE PURCHASE WARRANTS
NO. [Insert Warrant Certificate Number] [Insert Number of Warrants] WARRANTS
{{Month}} {{Day}}, 2020
THIS IS TO CERTIFY THAT for value received, [Insert Name of Investor] (the “Holder”) is entitled for each whole warrant represented hereby (each, a “Warrant”) to purchase one fully paid andnon-assessable Class B Preferred Share (“Share”) in the capital ofFUSION PHARMACEUTICALS INC. (the “Corporation”) at any time prior to 5:00 p.m. (Toronto time) on the earlier of: (a) the date that is two (2) years from the date hereof (or if such day is not a Business Day (as defined below), the next following Business Day); (b) the date upon which a Liquidation Event (as defined in the special rights and restrictions of the Shares) or a Share Sale (as defined in the Voting Agreement (as defined below)) has occurred; or (c) the date upon which the Holder becomes a Defaulting Purchaser (as defined in that certain Subscription Agreement dated March 25, 2019, as the same may be amended from time to time, by and among, among others, the Corporation and the Holder (the “Subscription Agreement”)) (the earlier of (a), (b) or (c), the “Expiry Time”), at an exercise price equal to US$1.5154 per Share (the “Exercise Price”). The number of Shares which the Holder is entitled to acquire upon exercise of the Warrants and the Exercise Price are subject to adjustment as hereinafter provided.